Bayer CEO Confident of Reaching Adjusted Guidance

The transcript covers a discussion on forecast adjustments due to high inventories in Brazil, currency hedging strategies, and the impact of currency fluctuations. It also addresses the confidence in closing the Monsanto acquisition by year-end, regulatory challenges, and the performance of the healthcare business. The conversation highlights the company's strategic decisions, market conditions, and financial projections.

What was the primary reason for the company's revised 2017 forecasts?

• High market inventories in Brazil

• Regulatory changes

• New product launches

• Increased competition

How does the company plan to manage foreign exchange risks?

• By reducing international operations

• Through hedging strategies

• By diversifying investments

• By increasing product prices

What impact did currency fluctuations have on the company's financials?

• Increased investment opportunities

• No significant impact

• Positive impact on revenue

• Negative impact on top and bottom lines

What is the company's stance on the $66 billion Monsanto deal?

• They have decided to cancel the deal

• They are seeking new partners for the deal

• They are confident it will close by year-end

• They are reconsidering the deal

What potential concession might the company consider for the Monsanto deal?

• Selling the rapeseed business

• Reducing workforce

• Increasing product prices

• Expanding into new markets

What was a factor affecting the healthcare business's growth?

• New competitors entering the market

• One-time effects like order patterns

• Increased marketing expenses

• Regulatory hurdles

Despite challenges, what is the company's outlook for its healthcare business?

• They foresee significant losses

• They plan to divest the business

• They are confident with an unchanged guidance

• They expect a decline in performance